OBI-992 drug-linker

OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan (HY-13631) and a linker. OBI-992 drug-linker exhibits antitumor property in mouse models and can be used for synthesis of ADC OBI-992[1].

Product Specifications

CAS Number

[3039487-10-7]

UNSPSC

12352005

Target

Drug-Linker Conjugates for ADC

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

96.64

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C=CC1=O)N1CC2CCC(C(N[C@@H](CCC(N[C@H](C(N[C@H](C(NC3=CC=C(COC(N[C@H]4CCC5=C6C4=C7C(C(N8C7)=CC([C@](CC)(O)C(OC9)=O)=C9C8=O)=NC6=CC(F)=C5C)=O)C=C3)=O)C)=O)C(C)C)=O)C(NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)CC2

Molecular Formula

C106H162FN9O37

Molecular Weight

2173.46

References & Citations

[1]Li WF, et al., OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models. Mol Cancer Ther. 2025 Feb 4;24 (2) :163-175.